These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35580172)

  • 1. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
    Calabretta E; Hamadani M; Zinzani PL; Caimi P; Carlo-Stella C
    Blood; 2022 Jul; 140(4):303-308. PubMed ID: 35580172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
    Goparaju K; Caimi PF
    Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
    Xu B
    Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
    Ahmed N; Hamadani M
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Baek GT; Huang IJ; Gopal AK
    Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
    Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Juárez-Salcedo LM; Nimkar S; Corazón AM; Dalia S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loncastuximab Tesirine: First Approval.
    Lee A
    Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
    Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
    Haematologica; 2024 Oct; 109(10):3314-3326. PubMed ID: 38721745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].
    Tauveron-Jalenques U; Bay JO
    Bull Cancer; 2023 May; 110(5):476-477. PubMed ID: 36949000
    [No Abstract]   [Full Text] [Related]  

  • 14. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
    Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loncastuximab tesirine for diffuse large B-cell lymphoma.
    Zurko J; Hamadani M
    Drugs Today (Barc); 2021 Dec; 57(12):733-743. PubMed ID: 34909802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
    Alderuccio JP; Sharman JP
    Blood Rev; 2022 Nov; 56():100967. PubMed ID: 35489963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma.
    Hess B; Townsend W; Ai W; Stathis A; Solh M; Alderuccio JP; Ungar D; Liao S; Liao L; Khouri L; Zhang X; Boni J
    AAPS J; 2021 Dec; 24(1):11. PubMed ID: 34893942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
    Alderuccio JP; Ai WZ; Radford J; Solh M; Ardeshna KM; Lunning MA; Hess BT; Zinzani PL; Stathis A; Carlo-Stella C; Hamadani M; Kahl BS; Ungar D; Kilavuz T; Yu E; Qin Y; Caimi PF
    Blood Adv; 2022 Aug; 6(16):4736-4739. PubMed ID: 35790100
    [No Abstract]   [Full Text] [Related]  

  • 19. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
    Davis JA; Shockley A; Glode AE
    J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
    [No Abstract]   [Full Text] [Related]  

  • 20. Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
    Hamadani M; Chen L; Song Y; Xu MK; Liao L; Caimi PF; Carlo-Stella C
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e738-e744. PubMed ID: 35513980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.